Blog

CM diabetes type 2

Here’s a current, practical (ADA-style) overview of diabetes screening and treatment, focused on what you actually use in primary care / correctional medicine.

1. Diabetes Screening Guidelines (ADA 2025-style)

Who to screen?

Screen ALL adults starting at age 35

  • even if asymptomatic

Screen earlier if overweight/obese (BMI ≥25, or ≥23 in Asian patients) PLUS risk factors, such as:

  • first-degree relative with diabetes
  • high-risk ethnicity
  • history of gestational diabetes
  • PCOS
  • hypertension
  • dyslipidemia
  • CVD
  • sedentary lifestyle
  • prediabetes history

Screening tests (any ONE of these is diagnostic if abnormal):

1. HbA1c

  • Normal: <5.7%
  • Prediabetes: 5.7–6.4%
  • Diabetes: ≥6.5%

2. Fasting plasma glucose

  • Normal: <100 mg/dL
  • Prediabetes: 100–125
  • Diabetes: ≥126

3. 2-hour OGTT (75 g)

  • Normal: <140
  • Prediabetes: 140–199
  • Diabetes: ≥200

4. Random glucose (with symptoms)

  • ≥200 + classic symptoms = diagnostic

Symptoms:

  • polyuria
  • polydipsia
  • weight loss

2. When to Start Treatment (Type 2 Diabetes)

Treatment depends on:

  • HbA1c
  • symptoms
  • comorbidities

First key concept:

You do NOT automatically start insulin at diagnosis.

Most patients start with:

  • lifestyle + metformin

3. First-Line Medication: METFORMIN

Why metformin is first line:

  • lowers glucose without causing hypoglycemia
  • weight neutral or mild loss
  • long safety record
  • inexpensive
  • possible cardiovascular benefit

When to start metformin:

Generally:

  • HbA1c ≥6.5% (diagnostic)
    OR
  • fasting glucose ≥126

Typical starting dose:

  • 500 mg daily or BID
  • titrate up to 1000 mg BID as tolerated

Contraindications / caution:

  • severe renal impairment (eGFR <30 → avoid)
  • severe liver disease
  • risk of lactic acidosis (rare but important)

Common side effects:

  • GI upset (very common)
  • diarrhea
  • metallic taste

Correctional medicine note:

Metformin is often interrupted on intake → restarting it appropriately is a high-yield intervention.

4. Second-Line Therapy (when metformin not enough)

If HbA1c remains above goal after ~3 months:

Choice depends on comorbidities.

Preferred add-on classes (modern guidelines)

1. GLP-1 receptor agonists (very important class)

Examples:

  • semaglutide
  • liraglutide
  • dulaglutide

Benefits:

  • weight loss
  • strong A1c reduction
  • cardiovascular benefit
  • low hypoglycemia risk

2. SGLT2 inhibitors

Examples:

  • empagliflozin
  • dapagliflozin

Benefits:

  • heart failure benefit
  • kidney protection
  • modest weight loss
  • glucose lowering

Choosing between them:

If obesity or weight loss desired → GLP-1 first

If heart failure or CKD → SGLT2 preferred

Other second-line options:

  • sulfonylureas (cheaper, but hypoglycemia risk)
  • DPP-4 inhibitors (modest effect, well tolerated)
  • TZDs (pioglitazone; edema/weight gain risk)

5. When to Start Insulin (Key Question)

This is the most clinically important threshold question.

Start insulin when:

1. Severe hyperglycemia:

  • HbA1c ≥10% OR
  • blood glucose ≥300 mg/dL

2. Symptoms of hyperglycemia:

  • polyuria
  • polydipsia
  • weight loss
  • fatigue
  • dehydration

3. Catabolic state:

  • ketosis
  • significant weight loss

4. Failure of oral therapy:

  • persistent A1c above goal despite multiple agents

Important nuance:

  • Type 2 diabetes does NOT automatically require insulin at diagnosis
  • But very high A1c (≥10%) often warrants early insulin

6. Insulin Basics (practical approach)

Initial regimen (Type 2 DM):

Basal insulin:

  • glargine OR detemir OR degludec

Start:

  • ~10 units nightly OR
  • 0.1–0.2 units/kg/day

Titration:

  • increase based on fasting glucose

Goal fasting:

  • ~80–130 mg/dL

When to add mealtime insulin:

  • if A1c still uncontrolled after basal optimization

7. HbA1c Treatment Targets

General target:

  • <7%

Less strict targets:

  • elderly
  • high hypoglycemia risk
  • multiple comorbidities

Target:

  • 7.5–8% or higher depending on situation

More strict targets:

  • younger patients
  • few comorbidities
  • long life expectancy

Target:

  • <6.5% (selected cases)

8. Diabetes in Correctional Medicine (Important Practical Issues)

You will frequently see:

1. Medication interruption on intake

  • metformin stopped
  • insulin regimen unknown
  • poor prior adherence

2. Undiagnosed diabetes

  • discovered via screening labs

3. Poor baseline control

  • A1c often very high (9–12%+)

4. Diet variability

  • institutional diet affects glucose control

5. Hypoglycemia risk

Especially with:

  • insulin
  • sulfonylureas

9. Summary Algorithm (Practical)

Step 1: Diagnose

  • A1c ≥6.5%

Step 2: Start metformin (if no contraindication)

Step 3: Reassess in ~3 months

  • If above goal → add GLP-1 or SGLT2 (or other agent)

Step 4: Consider insulin if:

  • A1c ≥10%
    OR
  • glucose ≥300
    OR
  • symptomatic hyperglycemia

Bottom Line

  • Screen adults starting at age 35 (earlier if high risk)
  • Diagnose with A1c ≥6.5%
  • First-line: metformin
  • Add GLP-1 or SGLT2 next based on comorbidities
  • Start insulin when:
    • A1c ≥10% OR glucose ≥300 OR symptomatic/catabolic state

If you want, I can next turn this into a correctional intake diabetes protocol (what to restart immediately on day 1 vs what to hold vs what labs to order) or a quick “insulin initiation cheat sheet.”